PKC downregulation upon rapamycin treatment attenuates mitochondrial disease.
PKC downregulation upon rapamycin treatment attenuates mitochondrial disease.
复制标题
DOI:
10.1038/s42255-020-00319-x
复制
发表时间:
2020-12
影响因子:
20.8
通讯作者:
Villén J
中科院分区:
文献类型:
--
作者:
Martin-Perez M;Grillo AS;Ito TK;Valente AS;Han J;Entwisle SW;Huang HZ;Kim D;Yajima M;Kaeberlein M;Villén J
Leigh syndrome is a fatal neurometabolic disorder caused by defects in mitochondrial function. mTOR inhibition with rapamycin attenuates disease progression in a mouse model of Leigh syndrome (Ndufs4 KO mouse); however, the mechanism of rescue is unknown. Here we identify PKC downregulation as a key event mediating the beneficial effects of rapamycin treatment of Ndufs4 KO mice. Assessing the impact of rapamycin on the brain proteome and phosphoproteome of Ndufs4 KO mice we find that rapamycin restores mitochondrial protein levels, inhibits signaling through both mTOR complexes, and reduces the abundance and activity of multiple protein kinase C (PKC) isoforms. Administration of PKC inhibitors increases survival, delays neurological deficits, prevents hair loss, and decreases inflammation in Ndufs4 KO mice. Thus, PKC may be a viable therapeutic target for treating severe mitochondrial disease. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
登录
查看更多内容
DOI:
10.1038/nrd3871
发表时间:
2012-12
期刊:
Nature reviews. Drug discovery
影响因子:
--
作者:
通讯作者:
--
影响因子:
16
作者:
Loewith, R;Jacinto, E;Hall, MN
通讯作者:
Hall, MN
DOI:
10.1073/pnas.1717065115
发表时间:
2018-02-13
影响因子:
11.1
作者:
Fang, Yimin;Hill, Cristal M.;Bartke, Andrzej
通讯作者:
Bartke, Andrzej
影响因子:
11.2
作者:
Darin, N;Oldfors, A;Tulinius, M
通讯作者:
Tulinius, M
影响因子:
64.8
作者:
Hebert-Chatelain, Etienne;Desprez, Tifany;Marsicano, Giovanni
通讯作者:
Marsicano, Giovanni